Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience.
Laura Gutierrez-SainzV Martinez-MarinD ViñalD Martinez-PerezJ PedregosaJ A Garcia-CuestaJ VillamayorP ZamoraA PintoA RedondoB CasteloP CruzO HigueraA CustodioA GallegoD Sanchez-CabreroJ de Castro-CarpeñoE EspinosaJ FeliuPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)
The incidence of VTE in cancer patients receiving immunotherapy in our study appeared to be similar to the incidence previously reported in other series of cancer patients treated with systemic therapies. VTE occurrence did not correlate with the prognosis. Further and prospective studies are needed to derive definitive conclusions.